ARVO Annual Meeting
May 3-7, 2026
Denver, USA
https://www.arvo.org/annual-meeting
Subscribe to our press distribution list to receive the latest news about AMW.
May 3-7, 2026
Denver, USA
https://www.arvo.org/annual-meeting
June 22-25, 2026
San Diego, USA
https://convention.bio.org/
July 6-9, 2026
Lisbon, Portugal
https://www.controlledreleasesociety.org/events/crs-2026-annual-meeting-exposition
July 8-10, 2026
Bangkok, Thailand
https://www.cphi.com/sea/en/attend/attend/why-attend.html
October 6-8, 2026
Milan, Italy
https://www.cphi.com/europe/en/exhibit/book-your-stand-milan.html
October 29-30, 2026
Boston, USA
https://poddconference.com/
November 9-11, 2026
Cologne, Germany
https://informaconnect.com/bioeurope/
May 22-24, 2025
Vienna, Austria
September 29 – October 1, 2025
Berlin, Germany
https://ipls.online/events/
October 28-30, 2025
Frankfurt, Germany
https://www.cphi.com/europe/en/home.html
February 5-6, 2026
London, UK
https://pharma-synergy-conference.com/pharmasynergy-2026/
March 2-3, 2026
Lisbon, Portugal
https://www.raucon.com/euro-plx/euro-p-l-x-90
March 23-25, 2026
Lisbon, Portugal
https://informaconnect.com/bioeurope-spring/
March 23-26, 2026
New York City, USA
https://dcatweek.org/
March 23-26, 2026
Prague, Czech Republic
https://worldmeeting.org/
March 24-27, 2026
Munich, Germany
https://analytica.de/de/muenchen/
This company ensures qualitythrough vocational training in several occupations.
read moreThe products are characterized by innovative applicators. Handling is easier, misapplications and painful injections are avoided.
read moreOn 28 August 2015, the BfArM granted approvals from DCP procedures for rivastigmin patches at doses 4.6 mg/24 h and 9.5 mg/24 h for Germany, Austria, Romania, Sweden, Slovakia and the Czech Republic.
read moreAMW GmbH (Arzneimittelwerk Warngau) has received follow-on financing to advance the development and commercialization process for its drug delivery systems. Together with BayBG Bayerische Beteiligungsgesellschaft, UnternehmerTUM-Fonds and IBG Beteiligungsgesellschaft, the existing investors are putting in a total of up to seven million euros. The funds will be used for the marketing of the existing product portfolio and the development of a new technology for the controlled release of pharmaceuticals. AMW GmbH produces active ingredient implants as well as transdermal systems in the fast-growing fields of oncology, pain therapy and neurology.
read moreAMW GmbH announces that another round of financing has been concluded with the existing shareholders. The funds are used to strengthen further growth and the development of innovative products. Dr. Wilfried Fischer, managing director of AMW GmbH, thanks for the trust of the shareholders in the performance of the company.
read moreYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Turnstile. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information